WaveMan
WaveMan · Company
CATX · Perspective Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CATX Perspective Therapeutics (CATX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000728387
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter

What the filings say about CATX

Insiders, 180 days
-$1.6M net sold
2 sellers · 0% of sales under a 10b5-1 plan

Perspective Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Perspective Therapeutics, Inc. insiders sold a net $1.6M of stock across 61 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lantheus Alpha Therapy, LLC
SELL
2026-09-08 SECtraded 2026-09-04
167,149
$526.1K
-60.2%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Sep 3, 2026.
  • The trade is 1.5% of the 11,273,364 shares held after it.
  • 1 other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lantheus Alpha Therapy, LLC sold about $526.1K of CATX on Sep 4, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 86 funds added in the latest 13F quarter.
Lantheus Alpha Therapy, LLC
SELL
2026-09-08 SECtraded 2026-09-03
80,783
$250.9K
-60.2%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Sep 2, 2026.
  • The trade is 0.7% of the 11,440,513 shares held after it.
  • 1 other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lantheus Alpha Therapy, LLC sold about $250.9K of CATX on Sep 3, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 86 funds added in the latest 13F quarter.
Lantheus Alpha Therapy, LLC
SELL
2026-09-04 SECtraded 2026-09-02
42,129
$131.2K
-61.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Sep 1, 2026.
  • The trade is 0.4% of the 11,521,296 shares held after it.
  • 1 other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lantheus Alpha Therapy, LLC sold about $131.2K of CATX on Sep 2, 2026; 1 other insider sold within 30 days and 86 funds added in the latest 13F quarter.
Lantheus Holdings, Inc.
SELL
2026-09-03 SECtraded 2026-09-01
35,769
$111.6K
-62.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 31, 2026.
  • The trade is 0.3% of the 11,563,425 shares held after it.
  • 1 other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lantheus Holdings, Inc. sold about $111.6K of CATX on Sep 1, 2026; 1 other insider sold within 30 days and 86 funds added in the latest 13F quarter.
Lantheus Alpha Therapy, LLC
SELL
2026-09-04 SECtraded 2026-09-01
35,769
$111.6K
-61.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 31, 2026.
  • The trade is 0.3% of the 11,563,425 shares held after it.
  • 1 other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lantheus Alpha Therapy, LLC sold about $111.6K of CATX on Sep 1, 2026; 1 other insider sold within 30 days and 86 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.6M over 180 days
-$1.6M over 90 days · -$1.6M of it by a 10%+ holder
below 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-7191.1% net margin
below 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.4% of the float short (float per yahoo 2026-10-26) · 5.5 days to cover · settled 2026-09-30
more than 84% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CATX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-58.7%12M
-59%-7%+45%+96%2025-102025-122026-022026-042026-062026-082026-10 2026-09-04 · Lantheus Alpha Therapy, LLC sold $526.1K2026-09-03 · Lantheus Alpha Therapy, LLC sold $250.9K2026-08-31 · Lantheus Holdings, Inc. sold $245.6K2026-08-31 · Lantheus Alpha Therapy, LLC sold $245.6K2026-09-02 · Lantheus Alpha Therapy, LLC sold $131.2K2026-09-01 · Lantheus Holdings, Inc. sold $111.6K2026-09-01 · Lantheus Alpha Therapy, LLC sold $111.6K2025-11-13 · Hunt Jonathan Robert bought $22.3K2025-11-12 · Williamson Robert F III bought $19.9K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CATX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
9,494,152 sh
$32.4M
TCG Crossover Management, LLC
7,915,567 sh
$27.0M
Commodore Capital LP
6,336,782 sh
$21.6M
Avidity Partners Management LP
6,299,999 sh
$21.5M
STATE STREET CORP
6,051,771 sh
$20.6M

Congress trades in CATX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CATX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CATX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Voya MI Dynamic Small Cap Fund
$416.9K position · as of 2026-05-31
0.2%
VOYA SMALL COMPANY PORTFOLIO
$401.8K position · as of 2026-06-30
0.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$13.8M position · as of 2026-06-30
0.1%
PROFUND VP BIOTECHNOLOGY
$61.0K position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$170.5K position · as of 2026-06-30
0.1%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$112.0K position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
3
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.6M sold by insiders over 180 days, 86 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CATX financials

Net margin
-7191.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4M
four quarters, 2023-01-01 to 2023-12-31
Net margin, TTM
-8,120%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$121.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-58.28x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-39.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$88.9M
market value at close 2026-10-27 on 2026-08-05 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-89.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$1.4M$0
Gross profitn/an/a$1.4M$0
Operating income-$113.6M-$90.9M-$40.9M-$8.7M
Net income-$103.1M-$79.3M-$46.5M-$10.8M
EPS (diluted)-1.40-1.23-1.74n/a
Operating cash flow-$82.5M-$18.3M-$36.9M-$10.4M
Cash$30.6M$61.6M$9.2M$21.0M
Long-term debt$1.6M$1.7M$1.7Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

CATX Stock Sonar score 5/7 axes

Find similar shapesCompare

CATX ranks highest on institutional and government (63rd percentile) and profitability (59th), and lowest on risk and compliance (14th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
59
Inputs
  • Return on equity-39.5% · 61 pct, sector of 545
  • Return on assets-33.1% · 57 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.3% · 60 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.00x · 80 pct, sector of 352
  • Cash flow to debt-58.28x · 10 pct, sector of 371
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.6M · 31 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
63
Inputs
  • Funds adding, latest quarter86 · 63 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
14
Inputs
  • Short interest, % of float+23.4% · 10 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+19.4% · 18 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CATX filings, in plain words

Are Perspective Therapeutics insiders buying or selling CATX?

In the 180 days to 2026-10-28, Perspective Therapeutics insiders were net sellers, a net $1.6M across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Perspective Therapeutics insiders were net sellers of CATX, a net $1.6M across purchases and sales reported on Form 4 by 2 sellers. Most of that figure, $1.6M, came from a holder of 10% or more rather than an officer or director. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies